GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Equity-to-Asset

Hemogenyx Pharmaceuticals (LSE:HEMO) Equity-to-Asset : 0.46 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Hemogenyx Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £2.82 Mil. Hemogenyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was £6.11 Mil.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

LSE:HEMO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.33   Med: 0.46   Max: 1
Current: 0.46

During the past 9 years, the highest Equity to Asset Ratio of Hemogenyx Pharmaceuticals was 1.00. The lowest was -0.33. And the median was 0.46.

LSE:HEMO's Equity-to-Asset is ranked worse than
67.33% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs LSE:HEMO: 0.46

Hemogenyx Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Equity-to-Asset Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Feb15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only -0.33 0.33 0.96 0.46 0.46

Hemogenyx Pharmaceuticals Semi-Annual Data
Feb15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.88 0.46 0.51 0.46

Competitive Comparison of Hemogenyx Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Equity-to-Asset falls into.



Hemogenyx Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Hemogenyx Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.819/6.106
=

Hemogenyx Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.819/6.106
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemogenyx Pharmaceuticals  (LSE:HEMO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Hemogenyx Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines